Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

6Total
Not Applicable (1)
Early P 1 (1)
P 1 (3)
P 2 (1)

Trial Status

Recruiting3
Active Not Recruiting2
Unknown2

Clinical Trials (7)

Showing 7 of 7 trials
NCT02677064Recruiting

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

NCT06265545Not ApplicableRecruiting

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

NCT03179930Phase 2Active Not Recruiting

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

NCT03085173Phase 1Active Not Recruiting

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

NCT06732232Early Phase 1RecruitingPrimary

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

NCT03881761Phase 1Unknown

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

NCT03881774Phase 1Unknown

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Showing all 7 trials

Research Network

Activity Timeline